VanEck JP Morgan EM Local Currency Bond ETF vs Edwards Lifesciences Corporation Common Stock — how do they compare? VanEck JP Morgan EM Local Currency Bond ETF trades at $24.8 (market cap $4.93B), while Edwards Lifesciences Corporation Common Stock trades at $83.76 (market cap $48.56B). The key difference: Edwards Lifesciences Corporation Common Stock is far larger — about 9.8× VanEck JP Morgan EM Local Currency Bond ETF's market cap, and Edwards Lifesciences Corporation Common Stock is trading nearer its 52-week high, VanEck JP Morgan EM Local Currency Bond ETF nearer its low. Which is the better fit depends on your goals.
| EMLC | EW | |
|---|---|---|
Market Cap | $4.93B | $48.56B |
Volume | 2,843,860 | 6,520,488 |
Sector | Fixed Income | Health |
52-Week High | $26.59 | $95.18 |
52-Week Low | $24.53 | $72.65 |
Typical Hold Time | 38 Days | — |
Enterprise Value | — | $45.01B |
Signals from Pluang's Aura AI — not financial advice
EMLC trades at $24.77, down 0.24% on the day and hitting a new 52-week low. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators remain neutral. The ETF faces headwinds from dollar strength and Fed rate hike expectations, though emerging market bonds have shown relative outperformance in 2026. Recent dividends of $0.14 and $0.13 were declared for October and August 2026 respectively.
The outlook remains cautious as dollar strength and rising global bond yields create challenges for emerging market local currency debt. While diversification benefits exist, near-term performance depends on currency dynamics and Federal Reserve policy direction. Key risks include currency volatility and global interest rate movements affecting bond valuations.
No Aura AI signal available yet.
Trailing returns across standard periods
EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.
Read more on EMLC →Edwards Lifesciences develops medical technologies for structural heart disease. Its products include transcatheter aortic-valve replacement, mitral and tricuspid therapies, and surgical structural-heart technologies.
Read more on EW →